Evolus (NASDAQ:EOLS) Stock Price Down 2.4% – Time to Sell?

Shares of Evolus, Inc. (NASDAQ:EOLS) traded down 2.4% during mid-day trading on Monday . The stock traded as low as $12.80 and last traded at $12.72. 41,269 shares changed hands during trading, a decline of 93% from the average session volume of 590,097 shares. The stock had previously closed at $13.03.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Barclays increased their target price on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Evolus in a research note on Wednesday, March 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Evolus in a research note on Wednesday, March 5th.

Evolus Price Performance

The stock has a market capitalization of $790.39 million, a price-to-earnings ratio of -13.66 and a beta of 1.28. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The company has a 50-day simple moving average of $13.55 and a two-hundred day simple moving average of $13.84.

Insider Activity at Evolus

In related news, CFO Sandra Beaver sold 8,996 shares of Evolus stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $119,286.96. Following the sale, the chief financial officer now directly owns 173,583 shares in the company, valued at $2,301,710.58. The trade was a 4.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $60,147.36. Following the completion of the sale, the chief marketing officer now directly owns 95,671 shares of the company’s stock, valued at $1,268,597.46. The trade was a 4.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 54,324 shares of company stock worth $716,856 in the last ninety days. 6.10% of the stock is owned by insiders.

Institutional Trading of Evolus

Hedge funds and other institutional investors have recently made changes to their positions in the stock. KBC Group NV bought a new position in shares of Evolus in the fourth quarter valued at approximately $49,000. IFP Advisors Inc raised its holdings in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock worth $52,000 after purchasing an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Evolus in the fourth quarter worth approximately $106,000. Rafferty Asset Management LLC bought a new position in Evolus during the 4th quarter valued at $115,000. Finally, Quantbot Technologies LP acquired a new position in shares of Evolus during the 4th quarter valued at $118,000. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.